Methods of activating cells via PTP 1B inhibition
AssigneesMonash University, Peter MacCallum Cancer Institute
InventorsTony Tiganis, Florian Wiede
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to methods of activating cells for use in therapy. For example, the invention relates to preparing cells ex vivo for use in immunotherapy, particularly cancer immunotherapy. More specifically, the invention relates to methods for the preparation of leukocytes, particularly T cells through PTP1B inhibition, exhibiting cytotoxic properties for use in adoptive cell transfer. The invention also relates to cells and compositions including them for cancer immunotherapy. The invention also relates to methods of immunotherapy, particularly cancer immunotherapy.
Claims7
A method for treating cancer in a subject in need thereof comprising administering a PTP1B inhibitor and CAR-T cell therapy to the subject, wherein the PTP1B inhibitor enhances activation of the CAR-T cells, thereby potentiating an immune response suitable for the treatment of cancer, wherein the PTP1B inhibitor is administered prior to or after administering the CAR-T cell therapy.
Dependencies are inferred from the claim text.